eligibility_summary
Inclusion: Locally advanced/metastatic solid tumors with high MUC1, ≥1 measurable lesion (RECIST v1.1), ECOG ≤1, adequate organ function, willing to use highly effective birth control. Exclusion: prior ≥Grade 3 CRS, severe infusion reactions/allergies to study components, systemic infection within 14 days or symptomatic COVID-19, active leptomeningeal or untreated brain mets, active/relapsing autoimmune disease. Other criteria may apply.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial tests: 1) BGB-B3227 – a humanized IgG1 monoclonal antibody directed at the tumor-associated mucin MUC1, intended to bind MUC1 on cancer cells and engage Fcγ receptor–bearing effector cells (e.g., NK cells/macrophages) to mediate ADCC/CDC. 2) Tislelizumab (BGB-A317) – an anti–PD-1 IgG4 checkpoint inhibitor that blocks PD-1 to reinvigorate T‑cell activity. 3) Chemotherapy – standard cytotoxic agents per guidelines. Targets/pathways: MUC1 on epithelial tumor cells, Fc-mediated cytotoxicity via NK/macrophages, PD‑1 on T cells (checkpoint pathway). Study: Phase 1a/1b, BGB-B3227 alone, with tislelizumab, and with tislelizumab + chemotherapy in MUC1-high solid tumors.